Drug Trial Radar · NCT01039376
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy
Last checked: Nov 20, 2026Latest source record: Jul 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
480
Actual
Start
May 6, 2010
Primary completion
Feb 20, 2017
Study completion Jun 26, 2018
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 25, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine if maintenance therapy with ofatumumab would prolong remission in patients with CLL who have responded to second or third line treatment. This study would also evaluate the safety of ofatumumab maintenance compared to observation (the current standard of care). This study was co-developed with the HOVON and NORDIC CLL group and would be conducted as a collaborative effort with GSK.
Conditions
- Leukaemia, Lymphocytic, Chronic
Interventions
OfatumumabBiological
Ofatumumab for maintenance therapy as IV infusions every 8 weeks . The first dose was 300 mg followed 1 week later by 1000 mg and 1000 mg every 8 weeks thereafter for up to 2 years.
ObservationOther
Observation/Safety Evaluation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival, as Assessed by the InvestigatorTime frame: From randomization until progression or death (up to 79 months)
- Progression-free Survival, as Assessed by the Independent Review Committee (IRC)Time frame: From randomization until progression or death (up to 79 months)
Locations
203 sites in 25 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Gilbert, Arizona
Novartis Investigative Site
Tucson, Arizona
Novartis Investigative Site
Tucson, Arizona
Novartis Investigative Site
Jonesboro, Arkansas
Novartis Investigative Site
Berkeley, California
Novartis Investigative Site
La Verne, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
San Pablo, California
Novartis Investigative Site
Hartford, Connecticut
Novartis Investigative Site
Gainesville, Florida
Novartis Investigative Site
Lake Worth, Florida
Novartis Investigative Site
Orlando, Florida
Novartis Investigative Site
Pembroke Pines, Florida
Novartis Investigative Site
West Palm Beach, Florida
Novartis Investigative Site
Macon, Georgia
Novartis Investigative Site
Savannah, Georgia
Novartis Investigative Site
Post Falls, Idaho
Novartis Investigative Site
Indianapolis, Indiana
Novartis Investigative Site
Iowa City, Iowa
Novartis Investigative Site
Westwood, Kansas
Novartis Investigative Site
Metairie, Louisiana
Novartis Investigative Site
Cumberland, Maryland
Novartis Investigative Site
Hagerstown, Maryland
Novartis Investigative Site
Worcester, Massachusetts
Novartis Investigative Site
Detroit, Michigan
Novartis Investigative Site
Springfield, Missouri
Novartis Investigative Site
St Louis, Missouri
Novartis Investigative Site
Henderson, Nevada
Novartis Investigative Site
New Brunswick, New Jersey
Novartis Investigative Site
Albuquerque, New Mexico
Novartis Investigative Site
Albuquerque, New Mexico
Novartis Investigative Site
Mineola, New York
Novartis Investigative Site
Rochester, New York
Novartis Investigative Site
Chapel Hill, North Carolina
Novartis Investigative Site
Durham, North Carolina
Novartis Investigative Site
Philadelphia, Pennsylvania
Novartis Investigative Site
Greenville, South Carolina
Novartis Investigative Site
Chattanooga, Tennessee
Novartis Investigative Site
Knoxville, Tennessee
Showing 40 of 203 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.